Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aquivia Health vs DrBrainRx

Aquivia Health
Graded #80

Higher grade

vs+1.4000000000000057
DrBrainRx
Graded #104

Lower grade

The verdict

Aquivia Health takes it — 72.2/100 to 70.8/100, but only just.

Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded… DrBrainRx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAquivia Health +20
86
66
Dose & formulationAquivia Health +13
85
72
Clinical oversightDrBrainRx +23
64
87
Labs & monitoringDrBrainRx +11
53
64
FulfillmentAquivia Health +4
71
67
Contract termsDrBrainRx +6
55
61
Aquivia Health · left barDrBrainRx · right bar

The numbers

MetricAquivia HealthDrBrainRx
WeighScore72.2/10070.8/100
GradeCC
Scorecard rank#80#104
Semaglutide$149/mo$199/mo (all doses, compounded)
Tirzepatide$179/mo$299/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Aquivia Health

Graded #80 · C

Strengths

  • Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
  • Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
  • Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
  • Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
  • Self-pay model with no insurance required and no separate consultation fee

Where it loses points

  • No public list of states served — you must complete intake to learn if your state qualifies
  • No named 503A compounding pharmacy partner, limiting licensure verification
  • No LegitScript, PCAB, or BBB trust badges visible
  • Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
DrBrainRx

Graded #104 · C

Strengths

  • Founded and overseen by Dr. Sara Siavoshi — triple board-certified in Neurology, Headache Medicine, and Obesity Medicine
  • LegitScript certified with compounded medications from USP-certified 503B pharmacies
  • Flat-rate pricing — same monthly cost for all dose levels (dose escalation does not raise price)
  • 100% online with rapid approvals (~24-48 hours) and discreet shipping in 3–5 business days
  • Side-effect support, dose adjustments, and injection guides included with provider care

Where it loses points

  • Separate $25/month provider care fee (compounded track) on top of medication cost
  • Compounded medications are not FDA-approved individual drugs
  • Labs not required or included — no baseline bloodwork protocol disclosed
  • States served not published; no explicit list available
  • No dedicated coaching program beyond clinical dose management

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard